5-FU/FA
Folinic Acid/ Leucovorin
Capecitabine
Oxaliplatin
Irinotecan
Bevacizumab
ESO
Fatigue/asthenia (57%)
Neutropenia (54%)
Diarrhea (32%)
Epistaxis (31%)
Peripheral edema (25%)
Stomatitis (20%)
Proteinuria (17%)
Hypertension (25%)
Infusion-related reactions (16%)
Hypertension grade 3-4 (15%)
Thrombocytopenia (13%)
Hypoalbuminemia (11%)
NSCLC (plus docetaxel)
Neutropenia (55%)
Fatigue/asthenia (55%)
Stomatitis/mucosal inflammation
(37%)
Epistaxis (19%)
Febrile neutropenia (16%)
Peripheral edema (16%)
Thrombocytopenia (13%)
Lacrimation increased (13%)
Hypertension (11%)
Cetuximab
Erythema (65%)
Acneiform dermatitis (57%)
Pruritus (57%)
Hypomagnesemia (39%)
Fatigue (26%)
Abdominal pain (25%)
Paronychia (25%)
Skin exfoliation (25%)
Nausea (23%)
Rash (22%)
Constipation (21%)
Diarrhea (21%)
Vomiting (21%)
Skin fissures (20%)
Cough (14%)
Dermatologic toxicity, Grade 3 and 4
(14% )
Acne (13%)
Peripheral edema (12%)
Regorafenib
Anemia (79%)
Increased AST (65%)
Asthenia (64%)
Proteinuria (60%)
Hypocalcemia (59%)
Hypophosphatemia (57%)
Lymphopenia (54%)
Decreased appetite and food intake
(47%)
Increased lipase (46%)
Hand-foot skin reaction (HFSR) [palmarplantar erythrodysesthesia] (45%)
Hyperbilirubinemia (45%)
Increased ALT (45%)
Diarrhea (43%)
Thrombocytopenia (41%)
Mucositis (33%)
Weight loss (32%)
Infection (31%)
Hypertension (30%)
Dysphonia (30%)
Hyponatremia (30%)
Pain (29%)
Fever (28%)
Rash (26%)
Hypokalemia (26%)
Increased amylase (26%)
Increased INR (24%)
Hemorrhage (21%)
Nausea (20%)
Trifluridine/ Tipiracil